Connect with us

Technology

Declaration on longevity and precision medicine launched at Abu Dhabi Global Health Week

Published

on

Establishing actionable frameworks to advance precision medicine and longevity scienceThe declaration highlights the impact longevity and precision medicine can have on supporting healthy communities, and engages leaders to work towards actionable solutions, drive consensus among global peers, and invest in long-term solutionsIt brings together leading healthcare and academic institutions to redefine and improve health outcomes while aligning on key global healthcare priorities

ABU DHABI, UAE, April 18, 2025 /PRNewswire/ — A groundbreaking ‘Declaration on Longevity and Precision Medicine’ was launched at Abu Dhabi Global Health Week (ADGHW), marking a historic milestone in the quest to transform healthcare delivery and research worldwide.

As the first initiative of its kind, and developed in collaboration with leading international health organisations, academic institutions, and industry pioneers, the declaration establishes key principles to accelerate the advancement of precision medicine and longevity science.

Speaking at the launch, H.E. Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi (DoH) stated: “Healthy populations lead to healthy communities, stronger social cohesion, and fuels economic growth. This declaration unites global leaders to harness emerging technologies responsibly and deliver the benefits of precision medicine to all. Because health knows no boundaries, we are working together towards actionable and long-term solutions.”

Developed in collaboration with experts worldwide, the declaration aims to drive the adoption of personalised care and promote research into extending healthy lifespans. It highlights the urgency of addressing the widening healthspan-lifespan gap, which currently stands at nearly a decade globally.  

The declaration comes at a critical time as the World Health Organization projects the global population aged 60 and older will double to 2.1 billion by 2050. Concurrently, the precision medicine market is expected to grow from $81 billion in 2023 to over $175 billion by 2030.

The United Arab Emirates (UAE) is rapidly emerging as a regional and global leader in the longevity market, driven by pioneering regulatory frameworks, investments in precision medicine, and groundbreaking initiatives such as the world’s first licensed Healthy Longevity Medicine Centre.  From $19 billion in 2020, the UAE’s longevity market is estimated to reach $32 billion by 2026.

The declaration outlines bold commitments to advance longevity science, artificial intelligence (AI), driven diagnostics, and personalised therapeutics. It sets forth six key pillars: advancing research and innovation, enhancing collaboration and knowledge-sharing, investing in education and workforce development, advocating for supportive policy and regulation, upholding ethics and responsible practices and engaging the public about longevity research and its implications for health and society.

Signatories who convened at ADGHW to formalise their commitment which was led by DoH included, M42, Masdar City, PureHealth, Illumina, NYU Abu Dhabi, University of Pennsylvania, Aldar, Children’s National Hospital, Burjeel, Children Hospital of Philadelphia, and the Institute for Healthier Living Abu Dhabi (IHLAD).

PwC Middle East, a strategic partner in the initiative, highlighted the global significance of this declaration in advancing global healthcare priorities.  Lina Shadid, Health Industries Leader, PwC Middle East stated: “The declaration on longevity and precision medicine provides a global blueprint for integrating AI, genomics, and precision healthcare into mainstream medical practice and within the health ecosystem, to accelerate the adoption of life-changing medical innovations worldwide.

The declaration reflects Abu Dhabi’s ongoing commitment to shaping the future of health through knowledge-sharing, investment in research, and the integration of emerging technologies. By convening global experts and institutions, DoH is ushering a new era of precision medicine —one that prioritises personalised and preventative care, and enhances quality of life for populations worldwide.

Governments, health organisations and relevant stakeholders worldwide are encouraged to sign this declaration. For more information, please visit: https://www.adghw.com/

ADGHW is a major government initiative from DoH and serves as a platform for innovation and collaboration under the theme ‘Towards Longevity: Redefining Health and Well-being.’ It places a strong emphasis on community-driven health and well-being, with a proactive approach centred around preventive, personalised, and holistic care. 

For media inquiries or interview opportunities, please contact:  
Maroun Farah, Senior Media Relations Manager, Weber Shandwick
E: mfarah@webershandwick.com 
T: +971 55 166 2557

For media inquiries, please contact: Mariam Al Marzooqi 
msalmarzooqi@doh.gov.ae, 
+971 50 536 6660 

Photo – https://mma.prnewswire.com/media/2668417/Declaration_on_longevity_precision_medicine.jpg
Logo – https://mma.prnewswire.com/media/2666335/Abu_Dhabi_Global_Health_Week_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/declaration-on-longevity-and-precision-medicine-launched-at-abu-dhabi-global-health-week-302432551.html

SOURCE Abu Dhabi Global Health Week

Continue Reading

Technology

WuXi Biologics Receives Double Honors at 2026 HERA for ESG Reporting and Environmental Excellence

Published

on

By

HONG KONG, Nov. 3, 2026 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced it received two Grand Awards at the ninth Hong Kong ESG Reporting Awards (HERA), winning Best ESG Report (Large-Cap) and Excellence in Environmental Positive Impact.

HERA celebrates excellence in sustainability reporting and ESG practices, with award categories spanning ESG governance, environmental and social impact, carbon neutrality, and workplace well-being. The program is independently judged by a panel drawn from academia, finance, sustainability advisory and regulatory backgrounds, promoting transparency, accountability and stakeholder trust.

Selected from 120 entries, WuXi Biologics was the only pharmaceutical company to receive a Grand Award this year. Its two honors recognize WuXi Biologics’ continual efforts to advance transparent, high-quality ESG disclosure and deliver measurable environmental progress across its global operations.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, “We are delighted to receive two HERA awards, which reflect our ongoing conviction that transparent ESG disclosure and strong environmental performance are integral to business resilience and long-term success. WuXi Biologics will continue to advance our ESG governance and Green CRDMO strategy, working with global partners to drive sustainable development across the value chain.”

Through its Green CRDMO solutions, the Company continues to embed sustainability principles throughout its biologics research, development, manufacturing, and operations. In 2025, WuXi Biologics’ near-term, long-term and net-zero greenhouse gas emissions reduction targets were validated by the Science Based Targets initiative (SBTi), covering Scope 1, 2 and 3 emissions and aligned with a 1.5°C pathway. Another honor WuXi Biologics recently received was being named to the 2026 Forbes China ESG 50 list for achievements in sustainable development, Green CRDMO solutions, and ESG digital innovation.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide*.

With over 14,000 employees in China, the United States, Ireland, Germany, and Singapore, including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence, WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients’ needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of June 30, 2026, WuXi Biologics is supporting 1064 integrated client projects, including 78 in Phase III and 28 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

*The winner of the “2026 Biologics CDMO of the Year” (Large CDMOs) (Life Science Connect / Outsourced Pharma)

*The winner of the “2026 Best Contract Development & Manufacturing Organization Award” (ABEA)

Contacts

ESG
esg@wuxibiologics.com

Media
PR@wuxibiologics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/wuxi-biologics-receives-double-honors-at-2026-hera-for-esg-reporting-and-environmental-excellence-302928803.html

SOURCE WuXi Biologics

Continue Reading

Technology

Only 54% of Consumers Trust That Black Friday Discounts Are Lower Than Normal as Promotion Fatigue Grows

Published

on

By

BCG’s Annual Black Friday Survey Finds 1 in 5 Consumers Actively Distrust Advertised Discounts22% Plan to Spend Less or Skip Year-End Sales EventsRetailer Reputation and Transparent Pricing Rank Among the Highest Factors for Building Consumer Trust; Influencer Recommendations Rank LastUse of Social Media as a Shopping Inspiration Source Falls 9 Points to 46%, While AI Rises Across All Surveyed Countries

BOSTON, Nov. 4, 2026 /PRNewswire/ — Only 54% of consumers trust that advertised Black Friday prices are genuinely lower than usual, and one in five actively distrust them, according to a new survey from Boston Consulting Group (BCG).

Promotion fatigue is also growing, with 22% of consumers planning to spend less or skip year-end sales events because they believe discounts are available all the time.

Despite growing skepticism around promotions, consumers haven’t raised the bar for what constitutes a good deal. The expected minimum discount for a good deal eased to about 30% (versus 32% in 2025).

These are among the findings of BCG’s sixth annual Black Friday Consumer Study, based on a survey of 10,220 consumers across ten countries. The report, titled For Year-End Sales Events, Trust Is the New Currency, examines shopping expectations and behaviors ahead of Singles’ Day, Black Friday, and Cyber Monday.

“Shoppers no longer take Black Friday discounts at face value. Nearly half are unconvinced that prices are actually lower,” said Nate Shenck, a BCG managing director and senior partner, and coauthor of the report. “Retailers can’t discount their way past that. The question this season is how to earn shoppers’ trust.”

Credibility and Proof Build Trust, Persuasion Does Not

BCG determined the factors that build consumer trust using a net trust score (calculated as the share of consumers who say a factor increases their trust in a deal, minus the share who say it decreases it):

Retailer reputation and money-back guarantees ranked highest, each with a net trust score of 65%Verified purchase reviews also ranked among the top trust builders (59%), followed by clear comparisons between regular and discounted prices (58%)At the bottom of the ranking, real-time scarcity messages scored just 8%, AI-generated review summaries 4%, and influencer recommendations only 3%

AI Is Displacing Social Media as an Inspiration Channel

Social media as an inspiration source for consumers declined nine percentage points to 46%, falling in every market surveyed, whereas AI as an inspiration source increased across all ten markets.

Planned AI usage reached 56% of shoppers this year, up eight points from 2025. Around 86% of users find it helpful, and 78% say it raises their likelihood of completing a purchase.

Consumers trust AI most for comparing prices across retailers (39%) and comparing product features (37%). Transactional tasks, such as filling in checkout details, are still developing as a common use case.

“Shoppers facing promotion fatigue are turning to AI to do the work of finding and comparing deals. AI is already beginning to replace influencers as a go-to source for inspiration,” said Jessica Distler, a BCG managing director and partner, and coauthor of the report. “That means retailers need to think as carefully about how their offers are found and verified as they do about the discounts themselves.”

Download the report here:
https://www.bcg.com/publications/2026/trust-matters-year-end-sales-events

Media Contact:
Kendall Kosten
kosten.kendall@bcg.com 

About Boston Consulting Group
Boston Consulting Group bridges the gap between ambition and outcomes for the world’s leading companies and organizations. We are built for this era of unprecedented change — bringing strategic clarity rooted in over 60 years of deep domain knowledge, combined with applied AI shaped by our practitioners. BCG works shoulder-to-shoulder with CEOs across industries and geographies to deliver transformative impact at scale: stronger returns, transferred capabilities, and change that sticks. For more information, visit bcg.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/only-54-of-consumers-trust-that-black-friday-discounts-are-lower-than-normal-as-promotion-fatigue-grows-302928764.html

SOURCE Boston Consulting Group (BCG)

Continue Reading

Technology

Most Robots Still Aren’t Insured. YAS and Robolist Are Changing That.

Published

on

By

YAS and Robolist.ai partner to bring a free Risk Score and a path to insurance to robotics companies, giving firms, investors, and buyers a safer, more transparent foundation for an industry entering mass production

HONG KONG, Nov. 4, 2026 /PRNewswire/ — Artificial intelligence’s next phase is getting a body. Humanoid robot shipments are up sharply in 2026, with global shipments reaching roughly 30,000 units in the first half of the year alone, nearly 300% higher than a year earlier. But humanoids are only the headline category. Robolist.ai (“Robolist”), an independent market intelligence layer for robotics used by investors worldwide, tracks more than 4,200 robots from over 1,300 manufacturers across categories including industrial arms, warehouse AMRs, cobots, commercial cleaning, delivery, hospitality, and home robots, and growth is accelerating across nearly all of them.

Across every one of those categories, most of what is shipping today carries no insurance. YAS, a data risk intelligence platform that helps insurers underwrite EV, robotaxi, and now robotics risk, today announced a strategic partnership with Robolist to close that gap — starting with a free Risk Score for the companies Robolist already ranks, and a path to coverage for those who want one.

Putting safety first, for an industry still finding its footing

Robotics is moving from pilots to mass production, and that shift changes who is exposed and what’s at stake. YAS and Robolist both see the same underlying problem: an industry growing faster than the risk infrastructure built to support it. Pairing YAS’s risk intelligence with Robolist’s independent market data gives the industry one more layer of transparency, a shared, safety-first foundation that the companies believe is necessary for robotics to grow into a trusted, durable category rather than a fast-moving one with uneven guardrails.

What it means for robotics firms

Every manufacturer listed on Robolist is already independently ranked. Starting with this partnership, any of them can also request a free Risk Score, built with YAS, covering their systems across whichever category they operate in, not just humanoid. A strong, transparent risk profile is becoming a competitive advantage in its own right, a signal to enterprise buyers and partners that a company takes safety seriously. There is no cost to check it and no obligation attached.

What it means for investors

Robolist’s independent data has always given investors a clear picture of what a company has actually raised and shipped. Adding YAS’s Risk Score introduces a second, forward-looking signal: a working estimate of operational risk exposure, sitting alongside funding and deployment evidence. Together, the two offer a more complete basis for diligence, and support the kind of informed, patient capital that helps the category grow in a healthy, sustainable way rather than on hype alone.

What it means for buyers

Enterprises deciding whether to deploy a robot fleet have historically had almost no independent way to compare risk across vendors. The Risk Score gives buyers a transparent reference point alongside Robolist’s existing rankings, and a direct route to insurance for the deployments they choose to move forward with, so adoption decisions can be made with more confidence and less guesswork.

Status

The partnership is in its exploratory phase under a signed Memorandum of Understanding, beginning with Hong Kong, with other markets under consideration as it develops. The Risk Score is an indicative analytical tool, not a safety certification or a guarantee of coverage; insurance, where available, is issued by licensed carriers.

Quotes

“Robotics is scaling faster than the risk infrastructure around it. You can’t insure what you can’t measure — so we start by measuring. A free Risk Score, built on live operating data, gives every robotics company a transparent read on their exposure and, when they want it, a path to coverage. That’s how a fast-moving category becomes a durable one.”— Andy Ann, Founder, YAS

“We built Robolist as an independent market intelligence layer for robotics. Partnering with YAS deepens that layer. There’s a lot of natural overlap between what we do. Robotics insurance is a long-term project that benefits everyone in the industry, and it matters more now that the category is moving into mass production. Part of that is simply caring about what happens to the people and businesses actually using these machines.” — Matthew Cheung, Co-founder, Robolist.ai

About YAS

YAS is a Hong Kong-based risk intelligence platform for the machine economy, turning live operating data from vehicles, fleets, and robots into real-time risk scores used by licensed insurers to underwrite fairer, faster coverage. YAS works with insurance carrier partners across robotics and humanoids, EV and commercial fleets, with autonomous vehicles next.

About Robolist.ai

Robolist.ai is an independent market intelligence layer for robotics, used by investors to track what manufacturers actually raise, ship, and deploy. Robolist tracks more than 4,200 robots from over 1,300 manufacturers across categories from humanoids and industrial arms to cleaning, delivery, and home robots.

Learn more

Manufacturers can claim their profile and request a free Risk Score, and investors and buyers can explore the data, at robolist.ai. To learn more about YAS’s risk intelligence platform, visit yas.io.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/most-robots-still-arent-insured-yas-and-robolist-are-changing-that-302928742.html

SOURCE YAS

Continue Reading

Trending